Kris Cameron Wood

Associate Professor of Pharmacology and Cancer Biology

Our laboratory uses genomic and pharmacological approaches to understand how tumor dependencies are shaped by cell intrinsic factors, environmental factors, and drug treatments during the dynamic process of tumor evolution. To learn more, please visit our laboratory website: https://woodlabduke.com/.

Appointments and Affiliations

  • Associate Professor of Pharmacology and Cancer Biology
  • Associate Professor of Cell Biology
  • Member of the Duke Cancer Institute
  • Core Faculty in Innovation & Entrepreneurship

Contact Information

  • Email Address: kris.wood@duke.edu
  • Websites:

Education

  • Ph.D. Massachusetts Institute of Technology, 2007

Courses Taught

  • CMB 710B: Cell & Molecular Biology Module II
  • CMB 710D: Cell & Molecular Biology Module IV
  • MOLCAN 818: Molecular Mechanisms of Oncogenesis
  • PHARM 394: Research Independent Study
  • PHARM 493: Research Independent Study
  • PHARM 494: Research Independent Study
  • PHARM 495: Research Independent Study
  • PHARM 818: Molecular Mechanisms of Oncogenesis
  • UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I
  • UPGEN 778D: University Program in Genetics and Genomics Biological Solutions Module IV

In the News

Representative Publications

  • Maltas, Jeff, Shane T. Killarney, Katherine R. Singleton, Maximilian A. R. Strobl, Rachel Washart, Kris C. Wood, and Kevin B. Wood. “Drug dependence in cancer is exploitable by optimally constructed treatment holidays.” Nat Ecol Evol 8, no. 1 (January 2024): 147–62. https://doi.org/10.1038/s41559-023-02255-x.
  • Maltas, Jeff, Shane T. Killarney, Katherine R. Singleton, Maximilian A. R. Strobl, Rachel Washart, Kris C. Wood, and Kevin B. Wood. “Author Correction: Drug dependence in cancer is exploitable by optimally constructed treatment holidays.” Nat Ecol Evol 8, no. 1 (January 2024): 176. https://doi.org/10.1038/s41559-023-02300-9.
  • Wood, Kris, Daniel Nussbaum, Colin Martz, Andrew Waters, Alejandro Barrera, Justine Rutter, Christian Cerda-Smith, et al. “Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers.,” November 2, 2023. https://doi.org/10.21203/rs.3.rs-3511242/v1.
  • Stanland, Lyla J., Hazel X. Ang, Jacob P. Hoj, Yunqiang Chu, Patrick Tan, Kris C. Wood, and Micah A. Luftig. “CBF-Beta Mitigates PI3K-Alpha-Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer.” Mol Cancer Res 21, no. 11 (November 1, 2023): 1148–62. https://doi.org/10.1158/1541-7786.MCR-23-0034.
  • Stanland, Lyla J., Hazel X. Ang, Jacob P. Hoj, Yunqiang Chu, Patrick Tan, Kris C. Wood, and Micah A. Luftig. “Data from CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer,” November 1, 2023. https://doi.org/10.1158/1541-7786.c.6781964.